178 related articles for article (PubMed ID: 4046146)
1. Postmarketing follow-up: physicians have key role.
Goldsmith MF
JAMA; 1985 Oct; 254(16):2217. PubMed ID: 4046146
[No Abstract] [Full Text] [Related]
2. Risk Evaluation and Mitigation Strategy (REMS): FDA Perspective on What Physicians Need to Know.
Slatko GH
Am Fam Physician; 2015 Nov; 92(9):771-2. PubMed ID: 26554468
[No Abstract] [Full Text] [Related]
3. What you should know about FDA-USP Drug Product Problem Reporting Program.
McGinnis DM
Pharm Times; 1986 Apr; 52(4):101-4, 109. PubMed ID: 10276472
[No Abstract] [Full Text] [Related]
4. Adverse drug reaction reporting.
Bosco LA
Am J Gastroenterol; 1987 Apr; 82(4):356-7. PubMed ID: 3565343
[No Abstract] [Full Text] [Related]
5. Adverse-drug-reaction monitoring.
Faich GA
N Engl J Med; 1986 Jun; 314(24):1589-92. PubMed ID: 3713757
[No Abstract] [Full Text] [Related]
6. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.
Kessler DA
JAMA; 1993 Jun; 269(21):2765-8. PubMed ID: 8492403
[No Abstract] [Full Text] [Related]
7. Revised ADR report permits internal review of drug experience.
Jeffrey LP
Pharm Times; 1986 Dec; 52(12):48-50. PubMed ID: 10317827
[No Abstract] [Full Text] [Related]
8. Adverse drug event reporting. Improving the low US reporting rates.
Edlavitch SA
Arch Intern Med; 1988 Jul; 148(7):1499-503. PubMed ID: 3382293
[No Abstract] [Full Text] [Related]
9. [Postmarketing surveillance of drugs].
Simon P; Soubrié C
Rev Prat; 1983 Jan; 33(1-2):23-8. PubMed ID: 6823538
[No Abstract] [Full Text] [Related]
10. The Medical Device and Laboratory Product Problem Reporting Program.
Palkon DS
Hosp Top; 1987; 65(1):35-8. PubMed ID: 10282173
[TBL] [Abstract][Full Text] [Related]
11. A potential use of the National Death Index for postmarketing drug surveillance.
Edlavitch SA; Feinleib M; Anello C
JAMA; 1985 Mar; 253(9):1292-5. PubMed ID: 3968855
[TBL] [Abstract][Full Text] [Related]
12. Physician knowledge, attitudes, and behavior related to reporting adverse drug events.
Rogers AS; Israel E; Smith CR; Levine D; McBean AM; Valente C; Faich G
Arch Intern Med; 1988 Jul; 148(7):1596-600. PubMed ID: 3382304
[TBL] [Abstract][Full Text] [Related]
13. National Childhood Vaccine Injury Act: requirements for permanent vaccination records and for reporting of selected events after vaccination.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1988 Apr; 37(13):197-200. PubMed ID: 2832717
[No Abstract] [Full Text] [Related]
14. The growing role of epidemiology in drug safety regulation.
Hamburg MA
Epidemiology; 2011 Sep; 22(5):622-4. PubMed ID: 21811108
[No Abstract] [Full Text] [Related]
15. Postmarketing surveillance.
Oleen MA
Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449
[TBL] [Abstract][Full Text] [Related]
16. Leads from the MMWR. National Childhood Vaccine Injury Act: requirements for permanent vaccination records and for reporting of selected events after vaccination.
JAMA; 1988 May; 259(17):2527-8. PubMed ID: 2833628
[No Abstract] [Full Text] [Related]
17. Postmarketing surveillance methodologies.
Edlavitch SA
Drug Intell Clin Pharm; 1988 Jan; 22(1):68-78. PubMed ID: 3280280
[TBL] [Abstract][Full Text] [Related]
18. Postmarketing studies of drug efficacy: when must they be randomized?
Strom BL; Miettinen OS; Melmon KL
Clin Pharmacol Ther; 1983 Jul; 34(1):1-7. PubMed ID: 6861430
[No Abstract] [Full Text] [Related]
19. Adverse drug reaction processing in the United States and its dependence on physician reporting: zomepirac (Zomax) as a case in point.
Corre KA; Spielberg TE
Ann Emerg Med; 1988 Feb; 17(2):145-9. PubMed ID: 3257365
[TBL] [Abstract][Full Text] [Related]
20. MedWatch. On lookout for medical product problems.
Ropp KL
FDA Consum; 1993 Nov; 27(9):14-7. PubMed ID: 10130376
[No Abstract] [Full Text] [Related]
[Next] [New Search]
